Island Pharmaceuticals is an anti-viral drug development company focused on rational repurposing strategies for rapid development of prophylactic or therapeutic molecules targeting emerging viral threats. Island is developing a lead molecule, Isla101 for the prevention of dengue infections. Isla101 has been studied in 45+ clinical trials, primarily in cancer, but has yet to be approved for any indication. Relying on the vast publicly available clinical and pre-clinical data, as well as data from partners, Island is advancing directly to a Phase 2a clinical trial. In addition, Island has established research collaborations with two universities in Australia- Monash University and Griffith University, as well as Compounds Australia, which houses numerous small molecule libraries that will be screened in a variety if assays at the respective universities. This strategy complements development of Isla101 and provides a platform upon which Island is building its anti-viral pipeline.
Publicly Traded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):